| Document |
Document Title |
|
WO/2024/027553A1 |
The present invention relates to the field of biomedicine, and particularly to a bifunctional fusion protein and the use thereof. The bifunctional fusion protein comprises an Fc fragment, wherein one end of the Fc fragment is connected w...
|
|
WO/2024/031046A2 |
Fusion proteins are provided, which are composed of elements such as one or more proteins/polypeptides capable of translocating into an endoplasmic reticulum (ER) and an interleukin 18 (IL-18) or a fragment or variant of IL-18. The prote...
|
|
WO/2024/030479A1 |
The present invention provides a birth tissue derived implant for treating a subject. The birth tissue derived implant comprises a birth tissue and an agent exogenous to the birth tissue. The birth tissue is isolated from an amniotic sac...
|
|
WO/2024/026099A1 |
Novel methods, compositions, and kits for using lymph targeted antithrombotic (LTAT) molecules are provided herein. The LTAT molecules can be used for treating or preventing of lymphatic thrombosis resulting from infection or inflammatio...
|
|
WO/2024/023239A1 |
The present invention relates to a combination of nerve growth factor and sesamin, and uses thereof in the treatment of ophthalmic disorders.
|
|
WO/2024/023535A1 |
The present teaching relates to peptides that are capable of regulating the trafficking of leukocytes. This has applications in the treatment and/or prophylaxis of conditions associated with leukocyte migration, including inflammatory di...
|
|
WO/2024/026316A1 |
The disclosure relates to compositions comprising and methods of administration to a mammal of single guide RNA (sgRNA), tracrRNA and/or crRNA used individually or in combination with one another or Cas system components in order to trea...
|
|
WO/2024/023196A1 |
The present invention relates to the use of Antithrombin in the treatment of stroke.
|
|
WO/2024/022465A1 |
The present invention provides a human amylin polypeptide analogue comprising an unnatural amino acid and a derivative of the human amylin polypeptide analogue. The human amylin polypeptide derivative obtained by means of introducing an ...
|
|
WO/2024/022080A1 |
A use of a PLK4-targeting drug in the treatment of platinum drug-resistant tumors. Specifically, provided is a use of a PLK4-targeting drug in the preparation of a drug for treating an oxaliplatin-resistant cancer.
|
|
WO/2024/023771A1 |
Provided herein are methods of treating cancer in a human subject, comprising administering to the subject: i) an antibody-drug conjugate (ADC) comprising an antibody, a cleavable linker and a cytotoxic agent, and ii) a bispecific checkp...
|
|
WO/2024/026478A1 |
The present disclosure features compositions and methods for editing a 290-KD centrosomal protein (CEP290) gene to treat a congenital eye disorder, such as Leber's Congenital Amaurosis-10. In embodiments, the disclosure provides methods ...
|
|
WO/2024/026382A1 |
The present disclosure provides an improved yeast particle encapsulated nano-silica delivery system. The disclosure further provides methods of making and methods of using a nano-silica yeast particle delivery system.
|
|
WO/2024/023034A1 |
Lymphedema is a chronic condition causes by a lymphatic dysfunction that leads to the accumulation of fluid and fat in the limb. Here, the inventors identified the bioactive peptide apelin as good candidate to restore the lymphatic flow ...
|
|
WO/2024/025299A1 |
The present invention relates to a recombinant expression vector for CAT protein secretion and an Escherichia coli strain transformed therewith and provides: a recombinant expression vector carrying a flgM gene, a CAT gene, and a flhDC g...
|
|
WO/2024/025396A1 |
The present invention relates to an uristatin precursor drug and, more specifically, to an auristatin precursor drug bearing a self-immolative group, a preparation method therefor, a pharmaceutical composition comprising same, and a use ...
|
|
WO/2023/196220A9 |
Described herein are compositions comprising zinc fingers and methods of use thereof for the treatment of nucleotide repeat expansion disorders such as Ewing Sarcoma.
|
|
WO/2024/025875A2 |
Certain emboidments provide a method of promoting regeneration of one or more intestinal stem cells in a mammalian organoid culture, the method comprising treating the organoid culture with an effective amount of transforming growth fact...
|
|
WO/2024/026148A1 |
Provided are stapled peptides and conjugates thereof that have antibacterial activity against microbial pathogens that include, but are not limited to, multidrug-resistant bacteria. Also provided are stapled peptides and conjugates there...
|
|
WO/2024/026452A1 |
Provided herein are T cell epitopes associated with Type 1 diabetes. Also provided are antigen-presenting cells presenting such epitopes, T cells reactive to such epitopes, and related compositions and therapies.
|
|
WO/2024/026254A1 |
The disclosure features compositions, systems, and uses thereof, comprising polynucleotide(s) encoding target molecule(s), and polynucleotide(s) encoding repressor(s) or timer(s). The repressor(s) or timer(s) delay expression of the targ...
|
|
WO/2024/025474A1 |
The present disclosure concerns a polypeptide comprising a first three residue motif (from a N-terminus) and a second three residue motif, the first and second three residue motif optionally separated by 1 to 3 amino acid residue, and at...
|
|
WO/2024/024565A1 |
The present invention addresses the problem of providing an agent that suppresses cell aging and a drug that prevents or treats diseases and the like caused by cell aging. More specifically, the present invention is a cell aging suppress...
|
|
WO/2024/023715A1 |
The present invention relates to a topical composition comprising a cannabinoid, extracellular matrix component or extracellular matrix fragment, such as an extracellular polysaccharide that is hyaluronic acid, and a pharmaceutically acc...
|
|
WO/2024/025986A1 |
The invention provides pharmaceutical compositions of anti-PD-1 antibodies or antigen-binding fragments thereof with less than or equal to about 3.0 % oxidation of Met105 in the CDRH3 heavy chain region, and PH20 variants or fragments th...
|
|
WO/2024/026470A2 |
Provided, in part, are an anti-human transferrin receptor antigen-binding proteins and fusion proteins comprising an anti-human transferrin receptor antigen-binding proteins (e.g., in scFv, Fab or antibody format) which may be fused to a...
|
|
WO/2024/021383A1 |
The present invention relates to the field of disease treatment. In particular, the present invention provides a gp96 protein and use of a gp96 protein-constructed fusion protein in treating amyotrophic lateral sclerosis. In addition, th...
|
|
WO/2024/023521A1 |
The present disclosure is based in part on studies on novel tolerogenic peptides derived from a protein expressed by a pancreatic cell, which have been developed for use in antigen- specific immunotherapy for type 1 diabetes. Disclosed i...
|
|
WO/2024/025264A1 |
The present invention generally relates to a stem cell-derived extracellular vesicle (EV) comprising a signal regulatory protein (SIRP) and a method for preventing or treating cancer and/or inflammatory disease, condition, or symptom by ...
|
|
WO/2024/025204A1 |
The present invention relates to antibacterial protein S2200 which has specific antibacterial activity against Staphylococci including Staphylococcus aureus. More specifically, the present invention relates to: antibacterial protein S220...
|
|
WO/2024/026224A1 |
The present disclosure relates to methods, uses, compositions, and kits for improving muscle mass, muscle strength, or muscle function or for reducing fatigue, pain, or obesity in a subject using testosterone or testosterone derivative a...
|
|
WO/2024/026269A1 |
Methods for increasing expression of a target gene, the method comprising introducing a CCCTC-binding factor (CTCF) binding site (CTCF-BS) into a promoter region of the target gene, e.g., within 500, 250, 200, 150, 100, 50, or 25 nucleot...
|
|
WO/2024/026365A1 |
Described herein are topical cream formulations that include a C7–20 alkane, a metal chelating agent, and a buffer.
|
|
WO/2024/025207A1 |
The present invention relates to an antimicrobial protein SBL2200 having antimicrobial activity specific for Streptococci and, more specifically, to: a Streptococci-specific antimicrobial protein SBL2200 having the capacity to specifical...
|
|
WO/2024/026067A1 |
The present disclosure is directed to a method for treating a mammal with leaky gut syndrome or having pre-stages of leaky gut syndrome. The method includes administering a composition that includes a native or undenatured type II collag...
|
|
WO/2024/026490A1 |
The present disclosure provides isolated polynucleotides comprising multiple coding regions that are linked. In some aspects, a polynucleotide comprises at least a first coding region encoding a first antigen and a second coding region e...
|
|
WO/2024/025261A1 |
The present invention may provide a pharmaceutical composition for preventing or treating osteoarthritis, the composition comprising a carrier containing type 2 collagen peptide and rapamycin. Ideally, the composition may reduce inflamma...
|
|
WO/2024/022483A1 |
The invention belongs to the technical field of pharmaceutical synthesis and relates to a bifunctional pharmaceutical intermediate and a preparation method and use thereof. The invention discloses a compound of formula (A) and a variety ...
|
|
WO/2024/026329A2 |
Disclosed herein are compositions that include antigen-encoding nucleic acid sequences having multiple iterations of EGFR neoepitope-encoding sequences. Also disclosed are nucleotides, cells, and methods associated with the compositions ...
|
|
WO/2024/025989A1 |
The invention provides pharmaceutical compositions of anti-PD-1 antibodies or antigen-binding fragments thereof with less than or equal to about 3.0 % oxidation of Met105 in the CDRH3 heavy chain region, and rHuPH20 or variants or fragme...
|
|
WO/2023/220748A9 |
Endoscopic surgery targeted at the sinuses and nasal turbinates assists in managing the symptoms of chronic rhinosinusitis and other conditions. With contemporary techniques, post-operative hemorrhage, synechiae formation and poor wound ...
|
|
WO/2024/023745A1 |
The present invention pertains to the use for treating organ injury, in particular acute organ injury, such as acute kidney injury (AKI) using CD39, human recombinant CD39 and variants thereof.
|
|
WO/2024/025209A1 |
The present invention relates to the antibacterial protein SBL200 with specific antibacterial activity against Streptococci. More specifically, the present invention concerns Streptococcus-specific antibacterial protein SBL200, and a com...
|
|
WO/2022/256516A9 |
Compositions for specifically cleaving target sequences in retroviruses include nucleic acids encoding a Clustered Regularly Interspace Short Palindromic Repeat (CRISPR) associated endonuclease and a guide RNA sequence complementary to a...
|
|
WO/2024/026280A1 |
Described herein are compositions and methods for manufacturing polymeric microneedle arrays crosslinked by phenylboronic acid (PBA)-diol complexes for glucose-responsive insulin delivery.
|
|
WO/2024/025435A1 |
The present invention relates to biotechnology and medicine, and more particularly to oncology, and can be used for treating tumours of different origins. Proposed is a hybrid protein molecule SRH-DR5-B containing at the N-terminus an an...
|
|
WO/2024/025206A1 |
The present invention relates to an antibacterial protein SSL200 having a specific antibacterial activity against Staphylococci including Staphylococcus aureus. More specifically, the present invention relates to: an antibacterial protei...
|
|
WO/2024/023068A1 |
The present invention concerns the use of a molecule chosen from a globin, a globin protomer or an extracellular hemoglobin of Annelids, for treating and/or preventing at least one complement-activation associated disease, preferably isc...
|
|
WO/2024/020700A1 |
A combination therapy is provided involving potentiating the effects of an antigen presenting cell (APC) in a subject for treating cancer or for prophylactic treatment of cancer. The subject is co-administered with (1) said APC, (2) an i...
|
|
WO/2024/025479A1 |
A method of extraction of porcine placenta protein and development of encapsulating and transporting system of porcine placenta protein extract to control an enteric release is provide.The protein extract from porcine placenta is encapsu...
|
